Please login to the form below

Not currently logged in
Email:
Password:

Sun Pharma buys Taro Pharmaceuticals to increase US reach

Sun Pharmaceutical Industries has agreed to buy Israel-based generics firm, Taro Pharmaceutical Industries, for USD 230m in cash and an extra USD 224m (USD 454m) to refinance Taro's debt

India's largest pharmaceutical company, Sun Pharmaceutical Industries (Sun), has agreed to buy Israel-based generics firm, Taro Pharmaceutical Industries, for USD 230m in cash and an extra USD 224m (USD 454m) to refinance Taro's debt, according to a company statement release on 21 May.

Taro reported on 20 March that it would report a substantial loss in FY06, which would put it in breach of conditions on bank loans. The Taro acquisition will help Sun to expand its marketing network in the US, without having to establish a separate entity in the region. Sun anticipates an increase in the demand for generic drugs as healthcare costs increase and blockbuster drugs lose patent protection.

The acquisition will provide Sun with an extra 170 scientists and drugs for childhood illnesses and skin diseases. The company's shares rose INR 36.8 (USD 0.91), or 3.6 per cent, to INR 1,050 (USD 25.90) on the Mumbai Stock Exchange, gaining a total of 6.9 per cent so far in 2007.

Sun says it will use its profits and the proceeds from the USD 350m sale of bonds convertible into shares to fund the acquisition, which is subject approval by Taro shareholders and a regulatory review.

According to local media reports, Franklin Advisers and Templeton, who together hold a nine per cent share in Taro, filed a request for a temporary injunction against the deal on 19 May, adding that it could harm minority shareholders. The motion was heard on 21 May and a ruling is due soon.

Sun's USD 7.75-a-share offer values Taro at 27 per cent higher than its closing price of USD 6.10 on 18 May. Taro shares have lost 86 per cent of their value over the past three years.

Sun reported robust financials for the year ending 31 March 2007, with net sales were INR 21.3bn (USD 528.8m), a 30 per cent increase from INR 16.4bn (USD 406.9m) in the year ending 31 March 2006. Sun's international business grew 39 per cent, while EBITDA margin increased to 32.7 per cent from 30.8 per cent in the previous financial year, despite a 51 per cent increase in R&D revenue expense. Net profit was INR 7.7bn (USD 192.1m), an increase of 35 per cent, while Sun's net margin at 37 per cent for the year ending 31 March 2007 was higher than the previous year.

23rd May 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics